Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Sigma-Aldrich has inked a deal to acquire BioReliance, a provider biopharmaceutical services, from Avista Capital Partners for $350m in cash.
Subscribe to our email newsletter
BioReliance provides services including biologic, specialized toxicology and animal health testing to pharmaceutical, biopharmaceutical, diagnostics.
BioReliance’s service is believed to help facilitate biological drug development, manufacturing and commercialization activities.
Sigma-Aldrich expects to strengthen its value proposition by adding BioReliance’s services which would have an impact on its ability to provide enhanced solutions for its biopharmaceutical customers.
The transaction is expected to close in the first quarter of 2012.
Sigma-Aldrich president and CEO Rakesh Sachdev said the company intends to enhance its product offering and technology platforms with a compelling and specialized services platform.
"The addition of BioReliance’s industry-leading QA/QC testing services enables us to support customers’ needs to determine the quality and integrity of biological drugs at every step of the development and manufacturing process,"Sachdev added.